Fatal hepatitis B reactivation in a patient receiving chemoradiation for cervical cancer.
Colin DimondAndreea NegroiuDavid M HughesJasmine PatelPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
There are currently no standardized guidelines for the screening of HBV infection or prophylaxis treatment algorithm for patients undergoing chemoradiation. When initiating treatment with immunosuppressive therapy, it is important to screen all patients for chronic HBV infection and to work with an interdisciplinary team of oncologists, hepatologists, and pharmacists to initiate prophylactic antiviral therapy and closely monitor to minimize the risk of HBV reactivation.
Keyphrases
- hepatitis b virus
- patients undergoing
- rectal cancer
- liver failure
- newly diagnosed
- ejection fraction
- locally advanced
- palliative care
- stem cells
- squamous cell carcinoma
- case report
- deep learning
- radiation therapy
- primary care
- replacement therapy
- chronic kidney disease
- patient reported outcomes
- peritoneal dialysis
- single cell